We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Famotidine in COVID-19 Treatment.
- Authors
Tasdemir, Canatan; Guclu, Ertugrul; Devran, Zeynep; Hotschka, El Medina; Aydemir, Yusuf; Ogutlu, Aziz; Karabay, Oguz
- Abstract
Objective: Famotidine is an H2 receptor antagonist (H2RA) and has been shown to have antiviral properties in in vitro studies. Pantoprazole is one of the proton pump inhibitors (PPI). In this study, it was aimed to compare the efficacy of famotidine with pantoprazole in the treatment of COVID-19. Methods: Patients who were hospitalized and given famotidine and pantoprazole treatment for at least 48 hours were included in the study. Demographic, clinical and laboratory findings of the patients were analyzed retroprospectively from the patient files. The patients were divided into two groups as the famotidine group and the pantoprazole group. The groups were compared in terms of the need for intensive care and mortality rates. In addition, among the groups, the number of patients with normal oxygen saturation at discharge, number of days needed for oxygen support, number of days with fever, and length of hospital stay were evaluated. Results: A total of 179 Covid-19 patients (85 famotidine, 94 pantoprazole) were included in the study. Demographic findings and other symptoms except dyspnea were similar in both groups. Dyspnea, chronic diseases, and the number of patients given steroids were higher in those who were given pantoprazole (p<0.05). Mortality and ICU need were similar in both groups (respectively; p=0.25, p=0.26). The number of days with fever, duration of hospitalization, and the number of days requiring oxygen support were less in those given famotidine (respectively; p=0.04, p=0.003, p=0.014). Conclusions: Famotidine did not reduce the need for intensive care and mortality in COVID-19 patients treated in the hospital. New therapeutic agents are needed to reduce disease severity and mortality.
- Subjects
DRUG efficacy; COVID-19; PANTOPRAZOLE; RETROSPECTIVE studies; COMPARATIVE studies; FAMOTIDINE; CRITICAL care medicine; LONGITUDINAL method; MEDICAL needs assessment
- Publication
Konuralp Medical Journal / Konuralp Tip Dergisi, 2021, Vol 13, p455
- ISSN
1309-3878
- Publication type
Article
- DOI
10.18521/ktd.935888